Semaglutide, a weekly injection for overweight or obesity, results in an average weight loss of 14.9% over 68 weeks when combined with lifestyle changes. In comparison, placebo leads to 2.4% weight loss. Nearly 9 out of 10 users lose at least 5% of their body weight.
See the scientific wording
In adults with overweight or obesity, semaglutide 2.4 mg administered once weekly for 68 weeks combined with lifestyle intervention is associated with a mean weight loss of 14.9% from baseline, compared to 2.4% with placebo, and 86.4% of participants achieving at least 5% weight reduction.
Correlational — new studies may shift this
Randomized trialsOne low-scoring study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Randomized Controlled TrialHuman2021
The study found that taking semaglutide once a week along with diet and exercise led to an average 15% weight loss, and most people lost at least 5% of their weight, just as the claim says.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Semaglutide mimics a natural hormone that tells the pancreas to release insulin when blood sugar is high, stops the liver from making too much sugar, and slows down how fast food leaves the stomach. It also acts on the brain to make you feel full and reduce appetite. All of these actions together lead to eating less and losing weight.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Semaglutide, a weekly injection for overweight or obesity, results in an average weight loss of 14.9% over 68 weeks when combined with lifestyle changes. In comparison, placebo leads to 2.4% weight loss. Nearly 9 out of 10 users lose at least 5% of their body weight.
Mechanism
1 studySemaglutide works by copying a natural hormone that makes you feel full, slows down digestion, and helps control blood sugar. This makes you eat less and lose a lot of weight.
Semaglutide mimics a natural hormone that tells the pancreas to release insulin when blood sugar is high, stops the liver from making too much sugar, and slows down how fast food leaves the stomach. It also acts on the brain to make you feel full and reduce appetite. All of these actions together lead to eating less and losing weight.
Semaglutide binds to and activates GLP-1 receptors on pancreatic beta cells, increasing insulin secretion in a glucose-dependent manner and suppressing glucagon release from alpha cells.
Activation of GLP-1 receptors in the hypothalamus and other brain regions reduces appetite and increases satiety, leading to decreased food intake.
GLP-1 receptor activation delays gastric emptying, which slows the absorption of nutrients and contributes to reduced postprandial glucose excursions and prolonged satiety.
The combined effects of reduced appetite, delayed gastric emptying, and improved glycemic control lead to a sustained negative energy balance and significant weight loss.
Evidence from Studies
Supporting (1)
Community contributions welcome
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
The study found that taking semaglutide once a week along with diet and exercise led to an average 15% weight loss, and most people lost at least 5% of their weight, just as the claim says.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Semaglutide 2.4 mg for Weight Loss in Overweight or Obese Adults
A systematic review of RCTs comparing semaglutide 2.4 mg weekly plus lifestyle intervention vs placebo plus lifestyle intervention in overweight or obese adults, with weight loss outcomes at 68 weeks. Includes meta-analysis of mean difference in weight loss and proportion achieving 5% or more weight loss.
Double-Blind Randomized Placebo-Controlled Trial of Semaglutide 2.4 mg for Weight Reduction in Overweight or Obese Adults
A double-blind RCT randomizing overweight or obese adults (BMI≥27 with comorbidity or BMI≥30) to semaglutide 2.4 mg subcutaneous weekly or placebo for 68 weeks, both groups receiving lifestyle intervention. Primary outcome: percent weight change from baseline. Secondary: proportion achieving ≥5%, ≥10%, ≥15% weight loss.
Prospective Cohort Study of Long-Term Weight Loss and Metabolic Outcomes with Semaglutide in Clinical Practice
A prospective cohort study of overweight or obese adults initiating semaglutide 2.4 mg weekly in clinical practice, compared to a matched cohort not receiving semaglutide, followed for at least 68 weeks. Outcomes: weight loss, metabolic parameters, cardiovascular events, discontinuation rates.